26 May 2023
: Case report 
RLS-0071 Moderated Elevated Myeloperoxidase Level and Activity in an Asymptomatic Subject in Clinical Trial RLS-0071-101
Unknown etiology, Educational Purpose (only if useful for a systematic review or synthesis)
Jessica M. Goss1BCDF*, Pamela Hair1ABCDF, Parvathi S. Kumar1ADEF, Ulrich Thienel1AG, Kenji Cunnion1ACDEFG, Alexander Ellis2AEDOI: 10.12659/AJCR.939803
Am J Case Rep 2023; 24:e939803
Table 3. Plasma myeloperoxidase (MPO) concentration and activity for subject 1504.
| Sample | MPO concentration (pmol/L)Analysis performed in duplicate | MPO activity (pmol/min/ml) Analysis performed in triplicate |
|---|---|---|
| Mean (std error) | Mean (std error) | |
| Pre-dose 1 | 142.0 (8.52) | 30.3 (5.34) |
| Pre-dose 9 | 80.8 (14.4) | 15.6 (1.02) |
| End-of-infusion dose 9 | 72.5 (28.0) | 11.5 (2.23) |
| 1 hour after dose 9 | 74.7 (16.8) | 8.49 (1.90) |
| 24 hours after dose 9 | 94.3 (19.4) | 13.6 (1.01) |